Rhododenol-induced Leukoderma
Conditions
Interventions
Bimatoprost would be applied on the target region. The number of times to apply on the skin would follow the same number of times at the end of previous study "
investigator initiated study of Rhododenol-induced Leukoderma"
Sponsors
Teikyo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed as Rhododenol-induced Leukoderma according to diagnostic criteria of Japanese Dermatology Association (meeting all contents of essential diagnostic criteria and meeting at least one content of minor diagnostic criteria) a) essential diagnostic criteria i) Used Rhododenol containing cosmetics ii) Not having Leukoderma before using Rhododenol containing cosmetics. Complete or incomplete depigmented area emerged after use of Rhododenol containing cosmetics on mostly Rhododenol applied area. b) Minor diagnostic criteria i) The enlargement of Leukoderma stopped within a month after withdrawal of Rhododenol containing cosmetics. ii) After withdrawal of Rhododenol containing cosmetics, at least part of Leukoderma became re-pigmented. 2) The participant of the previous study and who also completed the observation period. 3) From the point of view of the efficacy and safety, those who were considered resonable by pricipal investigator or sub-investigator to be included in the subsequent study. 4) Those subjects who want to participate in the subsequent study after completing the previous study. 5) All participants are fully explained about the aim, content and expected side effects of the study. After confirming the participants' understanding, written informed consent is taken under their free will.
Exclusion criteria
Exclusion criteria: 1) Age under twenty years old at the time of inforomed consent. 2) Those who were suspected of concomitant vitiligo vulgaris. 3) Those who show skin problems such as erythema at the site of target region. 4) Those subjects who were considered by the principal investigator or sub-investigator to be showing skin problem which might be related to previous study. 5) Those subjects who were considered by the principal investigator or sub-investigator to be difficult to comply with compliance. 6) Those who show allagic reaction against Bimatoprost. 7) Those women who are pregnant or possibly pregnant or during lactation or those who cannot agree with contraception during the study. 8) Those otherwise principal physician considered unsuitable to include in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of pigmentation after twelve months application of Bimatoprost on target region. | — |
Countries
Japan
Contacts
Public ContactYayoi tada
Teikyo University School of Medicine Department of Dermatology
Outcome results
None listed